ZGNX - ゾゲニクス (Zogenix Inc.)

ZGNXのニュース

   Zogenix, Inc. Announces Proposed Convertible Senior Notes Offering  2020/09/22 20:14:02 GlobeNewswire
EMERYVILLE, Calif., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX) today announced its intention to offer, subject to market and other…
   5 Stocks To Watch For June 26, 2020  2020/06/26 08:45:59 Benzinga Feeds
Some of the stocks that may grab investor focus today are: Nike Inc (NYSE: NKE ) reported a loss for the fourth quarter. The company’s earnings and sales results also missed analysts’ expectations. Nike shares declined 3.9% to $97.41 in the after-hours trading session. Zogenix, Inc. (NASDAQ: ZGNX ) reported the FDA approval of its new therapy for Dravet syndrome. Zogenix … Full story available on Benzinga.com
   FDA OKs Zogenix drug for rare childhood epilepsy (NASDAQ:ZGNX)  2020/06/26 02:37:08 Seeking Alpha
Zogenix (NASDAQ:ZGNX) says the Food and Drug Administration approved its Fintepla drug to treat seizures associated with Dravet syndrome, a rare form of ch
   Zogenix wins approval for new drug to treat rare type of childhood epilepsy  2020/06/26 00:05:11 STAT
The drug, called fintepla, is a liquid solution administered to children born with Dravet syndrome, a severe type of epilepsy.
   The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions  2020/06/21 18:53:47 Benzinga Feeds
Biotech stocks rebounded along with the broader market in the week ended June 19. The week was a busy one from the perspective of PDUFA dates, with the FDA issuing approvals for Merck & Co., Inc. (NYSE: MRK ) and Novartis AG (NYSE: NVS ), among others. The week also witnessed a flurry of activity on the IPO front. The following are key biotech catalysts for the unfolding week. Conferences American Association of Cancer Research, or AACR, Virtual Annual Meeting II: June 22-24 BMO 2020 Prescriptions for Success Healthcare Conference: June 23 American Thoracic Society, or ATS 2020 Virtual: Clinical Trials Session: June 24 BofA Securities Napa Biopharma Conference: June 24 Cowen FutureHealth Conference: June 24-25 PDUFA Dates The FDA is scheduled to rule on Karyopharm Therapeutics Inc's (NASDAQ: KPTI ) sNDA for Selinexor, which could expand the drug's label to include adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, who have received at least two prior therapies. (Tuesday) Zogenix, Inc.'s (NASDAQ: ZGNX ) NDA for Fintepla as a potential treatment candidate for seizures associated with Dravet syndrome is pending before the FDA, with the regulatory agency expected to rule on the drug by the June 25 …
   5 Stocks To Watch For June 26, 2020  2020/06/26 08:45:59 Benzinga Feeds
Some of the stocks that may grab investor focus today are: Nike Inc (NYSE: NKE ) reported a loss for the fourth quarter. The company’s earnings and sales results also missed analysts’ expectations. Nike shares declined 3.9% to $97.41 in the after-hours trading session. Zogenix, Inc. (NASDAQ: ZGNX ) reported the FDA approval of its new therapy for Dravet syndrome. Zogenix … Full story available on Benzinga.com
   FDA OKs Zogenix drug for rare childhood epilepsy (NASDAQ:ZGNX)  2020/06/26 02:37:08 Seeking Alpha
Zogenix (NASDAQ:ZGNX) says the Food and Drug Administration approved its Fintepla drug to treat seizures associated with Dravet syndrome, a rare form of ch
   Zogenix wins approval for new drug to treat rare type of childhood epilepsy  2020/06/26 00:05:11 STAT
The drug, called fintepla, is a liquid solution administered to children born with Dravet syndrome, a severe type of epilepsy.
   The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions  2020/06/21 18:53:47 Benzinga Feeds
Biotech stocks rebounded along with the broader market in the week ended June 19. The week was a busy one from the perspective of PDUFA dates, with the FDA issuing approvals for Merck & Co., Inc. (NYSE: MRK ) and Novartis AG (NYSE: NVS ), among others. The week also witnessed a flurry of activity on the IPO front. The following are key biotech catalysts for the unfolding week. Conferences American Association of Cancer Research, or AACR, Virtual Annual Meeting II: June 22-24 BMO 2020 Prescriptions for Success Healthcare Conference: June 23 American Thoracic Society, or ATS 2020 Virtual: Clinical Trials Session: June 24 BofA Securities Napa Biopharma Conference: June 24 Cowen FutureHealth Conference: June 24-25 PDUFA Dates The FDA is scheduled to rule on Karyopharm Therapeutics Inc's (NASDAQ: KPTI ) sNDA for Selinexor, which could expand the drug's label to include adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, who have received at least two prior therapies. (Tuesday) Zogenix, Inc.'s (NASDAQ: ZGNX ) NDA for Fintepla as a potential treatment candidate for seizures associated with Dravet syndrome is pending before the FDA, with the regulatory agency expected to rule on the drug by the June 25 …
   Zogenix Launches Shine Forward with Dravet, a New Source of Inspiring Ideas for Parents of Children Living with Dravet Syndrome  2020/05/15 12:00:00 GlobeNewswire
Unique tips and tools informed by the Dravet syndrome community are designed to help parents and siblings of a child with Dravet stay positive and connected.
   Data Quality Issues Continue to Delay Drugs Development  2020/03/16 14:22:22 Medium
In yet another case highlighting the failure of legacy data management systems in clinical trials, US-based pharma Zogenix’s application for the release of a drug to treat seizures associated with…
   Drug Stock Sinks Lower on FDA Delay  2020/02/27 18:48:55 Schaeffers Investment Research
The FDA pushed back Zogenix's application approval by three months
   The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy  2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
   The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement  2020/02/25 13:28:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 24) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) Co-Diagnostics Inc (NASDAQ: CODX )(received CE mark for its coronavirus test) COLLPLANT BIOTE/S ADR (NASDAQ: CLGN ) Gilead Sciences, Inc. (NASDAQ: GILD )(reacted to a statement from WHO that its experimental drug remdesivir could be the one drug that may have efficacy) NGM Biopharmaceuticals Inc (NASDAQ: NGM )( reacted to positive readout for its NASH drug) PAVmed Inc (NASDAQ: PAVM ) TELA Bio Inc (NASDAQ: TELA ) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Feb. 24) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) AngioDynamics, Inc. (NASDAQ: ANGO ) BioSig Technologies Inc (NASDAQ: BSGM ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Endologix, Inc.
   The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology  2020/02/11 12:23:06 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) )(reacted to better-than-expected results and comments that its deal to be acquired by AbbVie is on track to close by the first quarter) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) ChemoCentryx Inc (NASDAQ: CCXI ) Co-Diagnostics Inc (NASDAQ: CODX )(announced sales of its new coronavirus test ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD )(reacted to positive data readout from early-stage study of experimental drug to treat eye disorders) Masimo Corporation (NASDAQ: MASI ) Novartis AG (NYSE: NVS ) Pacira Biosciences Inc (NASDAQ: PCRX ) Principia Biopharma Inc (NASDAQ: PRNB ) PTC Therapeutics, Inc (NASDAQ: PTCT ) Revance Therapeutics Inc (NASDAQ: RVNC ) ResMed Inc.

calendar